<h2 data-section-id="1l6xu4t" data-start="0" data-end="56"><strong>Idiopathic Membranous Nephropathy Market Insights</strong></h2>
<p data-start="58" data-end="727"><strong><a href="https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-imn-market">Idiopathic Membranous Nephropathy (IMN)</a></strong> is a rare autoimmune kidney disorder with growing clinical attention due to advancements in biomarker-based diagnosis and targeted therapies. The IMN market across the 7MM was valued at nearly USD 130 million in 2025 and is projected to grow at a CAGR of 0.4% during 2026&ndash;2036. The United States accounted for approximately 60% of the total market share, driven by increasing diagnosis rates and improved disease awareness. Rituximab currently dominates the treatment landscape; however, emerging biologics and precision therapies are expected to gradually reshape future market dynamics and improve long-term disease management.</p>
<h3 data-start="729" data-end="754"><strong data-start="729" data-end="754">Key Market Highlights</strong></h3>
<ul data-start="755" data-end="1023">
<li data-section-id="13nfkn0" data-start="755" data-end="798">CAGR of 0.4% projected during 2026&ndash;2036</li>
<li data-section-id="k15zdo" data-start="799" data-end="850">7MM market size reached USD 130 million in 2025</li>
<li data-section-id="suijny" data-start="851" data-end="906">US accounted for nearly 60% of total market revenue</li>
<li data-section-id="eyh64d" data-start="907" data-end="956">Rituximab led the US treatment market in 2025</li>
<li data-section-id="svfk5d" data-start="957" data-end="1023">Biomarker-driven therapies are transforming disease management</li>
</ul>
<h3 data-section-id="d9gwpt" data-start="1030" data-end="1092"><strong>Idiopathic Membranous Nephropathy Epidemiology Insights</strong></h3>
<p data-start="1094" data-end="1756">Idiopathic Membranous Nephropathy remains a rare but increasingly recognized autoimmune renal disease associated with podocyte-targeting autoantibodies. In 2025, total diagnosed prevalent cases across the 7MM were estimated at approximately 69,500. The United States represented the largest patient pool with 42% of total cases, followed by EU4 and the UK at 35%, and Japan at 23%. Epidemiological trends are expected to rise steadily due to improved diagnostics and greater awareness of autoimmune kidney disorders. Advances in identifying PLA2R and THSD7A autoantibodies have significantly improved disease understanding, diagnosis, and patient stratification.</p>
<h3 data-start="1758" data-end="1789"><strong data-start="1758" data-end="1789">Key Epidemiology Highlights</strong></h3>
<ul data-start="1790" data-end="2087">
<li data-section-id="ccqu3i" data-start="1790" data-end="1858">Total diagnosed prevalent cases in the 7MM reached 69.5K in 2025</li>
<li data-section-id="106zgri" data-start="1859" data-end="1916">US accounted for approximately 42% of prevalent cases</li>
<li data-section-id="4qpcd" data-start="1917" data-end="1973">EU4 and the UK contributed nearly 35% of total cases</li>
<li data-section-id="y7sodi" data-start="1974" data-end="2030">Japan represented around 23% of diagnosed prevalence</li>
<li data-section-id="177mn10" data-start="2031" data-end="2087">Total treated IMN cases in the US reached nearly 35K</li>
</ul>
<h2 data-section-id="135hwkq" data-start="2094" data-end="2166"><strong>Idiopathic Membranous Nephropathy Pipeline and Emerging Therapies</strong></h2>
<p data-start="2168" data-end="2848">The IMN pipeline is gradually evolving with the development of targeted biologics, immune modulators, and therapies aimed at reducing autoimmune-mediated kidney damage. Although no specifically approved therapy currently exists for IMN, emerging treatments are focused on improving efficacy, reducing toxicity, and delaying progression to end-stage renal disease. Companies are increasingly exploring therapies targeting <a href="https://www.delveinsight.com/report-store/baff-and-april-targeted-therapies-market-forecast"><strong>APRIL/BAFF</strong></a> pathways, <a href="https://www.delveinsight.com/report-store/melanocortin-receptors-mcr-therapies-market-forecast"><strong>melanocortin receptors</strong></a>, and antibody-mediated immune mechanisms. The growing understanding of disease biomarkers and autoimmune pathways is expected to support the development of more personalized treatment approaches in the coming years.</p>
<h3 data-start="2850" data-end="2872"><strong data-start="2850" data-end="2872">Key Pipeline Drugs</strong></h3>
<ul data-start="2873" data-end="3310">
<li data-section-id="cso5yq" data-start="2873" data-end="2972"><strong data-start="2875" data-end="2894">SNP-ACTH (1-39)</strong> &mdash; Cerium Pharmaceuticals
<ul data-start="2924" data-end="2972">
<li data-section-id="z8hus9" data-start="2924" data-end="2972">Melanocortin receptor agonist | Subcutaneous</li>
</ul>
</li>
<li data-section-id="1n5bma9" data-start="2974" data-end="3070"><strong data-start="2976" data-end="2992">Povetacicept</strong> &mdash; Vertex/Ono Pharmaceuticals
<ul data-start="3026" data-end="3070">
<li data-section-id="1ws831q" data-start="3026" data-end="3070">APRIL and BAFF inhibition | Subcutaneous</li>
</ul>
</li>
<li data-section-id="1y87x44" data-start="3072" data-end="3139"><strong data-start="3074" data-end="3088">Budoprutug</strong> &mdash; Climb Bio
<ul data-start="3105" data-end="3139">
<li data-section-id="1begyqf" data-start="3105" data-end="3139">suPAR antagonist | Intravenous</li>
</ul>
</li>
<li data-section-id="cu3dqz" data-start="3141" data-end="3223"><strong data-start="3143" data-end="3153">GAZYVA</strong> &mdash; Hoffmann-La-Roche
<ul data-start="3178" data-end="3223">
<li data-section-id="1u0p81b" data-start="3178" data-end="3223">Antibody-dependent cell cytotoxicity | IV</li>
</ul>
</li>
<li data-section-id="12lixuw" data-start="3225" data-end="3310"><strong data-start="3227" data-end="3251">MOR202 (Felzartamab)</strong> &mdash; Biogen
<ul data-start="3265" data-end="3310">
<li data-section-id="1u0p81b" data-start="3265" data-end="3310">Antibody-dependent cell cytotoxicity | IV</li>
</ul>
</li>
</ul>
<h3 data-start="3312" data-end="3335"><strong data-start="3312" data-end="3335">Pipeline Highlights</strong></h3>
<ul data-start="3336" data-end="3635" data-is-last-node="" data-is-only-node="">
<li data-section-id="414ey" data-start="3336" data-end="3388">Increasing focus on biomarker-targeted therapies</li>
<li data-section-id="1a7cazw" data-start="3389" data-end="3448">Novel biologics and immune modulators under development</li>
<li data-section-id="3jxmb" data-start="3449" data-end="3505">Personalized treatment approaches gaining importance</li>
<li data-section-id="1u3k5o" data-start="3506" data-end="3566">SNP-ACTH expected to strengthen future treatment options</li>
<li data-section-id="16rz4zn" data-start="3567" data-end="3635" data-is-last-node="">Limited approved therapies creating significant market opportunity</li>
</ul>

Idiopathic Membranous Nephropathy Market

Idiopathic Membranous Nephropathy Infographics

Idiopathic Membranous Nephropathy Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape